Deals In Depth: May 2022

 
• By Deanna Kamienski and Maureen Riordan

In the top May alliance by deal value, Amphista Therapeutics and Bristol Myers Squibb aim to discover and develop targeted small-molecule protein degraders by leveraging Amphista's proprietary Eclipsys platform. BMS gets exclusive global rights to resulting products. Amphista will receive a $30M upfront payment, up to $1.25B in performance-based milestone payments, payment for a limited expansion of the collaboration, as well as royalties on global net sales.

Deals In Depth

On the same day the Bristol Myers Squibb Company collaboration was signed, Amphista Therapeutics penned a similar deal with Merck & Co., Inc. for protein degraders. The Merck agreement is worth up to $984m and was the fourth largest May alliance.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo